Research programme: wound healing therapeutics -Innocoll/TGR BiosciencesAlternative Names: TGR-265
Latest Information Update: 23 Sep 2010
At a glance
- Originator Innocoll; TGR BioSciences
- Mechanism of Action Collagen stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Wounds
Most Recent Events
- 23 Sep 2010 No development reported - Preclinical for Wounds in USA (Topical)
- 23 Sep 2010 No development reported - Preclinical for Wounds in USA (Implant)
- 12 Sep 2007 Preclinical trials in Wounds in USA (Topical)